AngioDynamics Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Value Chain Analysis
This AngioDynamics Value Chain Analysis gives you a clear view of how the company creates value through its support and primary activities. The page already shows a real preview of the analysis, so you can review the style and substance before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
AngioDynamics' firm infrastructure rests on corporate finance, legal, quality, and regulatory teams that keep a tightly controlled medtech business on track. In fiscal 2025, that backbone supported 2 reportable segments and a portfolio spread across multiple product families, so capital allocation and compliance had to stay tight.
Because the business sells into regulated clinical settings, these systems matter for execution, product approvals, and risk control. They also help AngioDynamics protect margins and manage working capital while serving hospitals and physicians across its core markets.
Human Resource Management
Human resource management at AngioDynamics is a core support activity because it must hire engineers, manufacturing staff, regulatory specialists, and commercial teams that understand clinical workflows and physician needs.
Training is critical in procedure-driven markets, where product safety, device handling, and customer confidence can directly affect adoption and repeat use.
Retention also matters because skilled talent supports quality, compliance, and faster product execution across AngioDynamics' medical device portfolio.
Technology Development
AngioDynamics creates value in technology development by turning R&D into differentiated minimally invasive devices for peripheral vascular disease, oncology, and other non-vascular uses. In fiscal 2025, it reported about $309 million in net sales and invested roughly $28 million in R&D, a sign it keeps funding product design and clinical evidence to improve outcomes and widen use cases.
Procurement
Procurement at AngioDynamics is a control point for specialized parts, sterile packaging, and outsourced services, all of which must meet strict medical-device quality rules. In FY2025, that discipline matters because the company must protect supply continuity, traceability, and cost while supporting products used in hospitals and procedure rooms.
For regulated devices, a weak supplier can halt production fast, so AngioDynamics needs tight qualification, audit, and lot-trace systems. That helps contain scrap, avoid recalls, and keep lead times stable when components are scarce.
AngioDynamics FY2025: $309M Sales, $28M R&D, Tight Control
AngioDynamics' support activities in fiscal 2025 centered on compliance-heavy infrastructure, skilled hiring, R&D, and controlled procurement. That mix supported about $309 million in net sales and $28 million in R&D spend, while helping the company run 2 reportable segments and protect product quality in regulated markets.
| FY2025 data | Value |
|---|---|
| Net sales | $309 million |
| R&D | $28 million |
| Reportable segments | 2 |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
AngioDynamics' inbound logistics centers on tightly controlled receipt of specialized components and materials that must meet medical-device specs before production. Each lot needs inbound inspection and traceability, because sterile and procedure-critical products depend on clean records and fast recall readiness. That matters in fiscal 2025 as the business kept shipping regulated devices where one bad input can halt a line and risk compliance.
Operations
AngioDynamics turns sourced materials into finished medical devices through assembly, testing, quality checks, and sterilization, and that work sits at the center of its angioplasty, thrombolysis, embolization, and other minimally invasive lines. In FY2025, AngioDynamics reported net sales of about $291 million, so tight process control matters for every shipped unit.
Operations also shape quality and margin: fewer defects, less scrap, and faster release to market support devices used in time-sensitive care. For a medtech maker with a relatively small revenue base, even small gains in yield and throughput can move profit more than raw volume growth.
Outbound Logistics
AngioDynamics ships devices through controlled channels to hospitals, outpatient centers, and distributor partners. In fiscal 2025, it generated about $300 million in net sales, so outbound logistics can affect revenue timing fast.
Timely fulfillment, inventory visibility, and sterile-pack handling help keep devices ready for scheduled and urgent procedures. That matters when a delayed shipment can push a case and strain near-term sales.
Marketing and Sales
AngioDynamics sells through a clinical, physician-facing model built around interventional radiologists, surgeons, and other physicians. That makes marketing and sales hinge on product education, strong account coverage, and proving procedural value in its three core disease areas. In FY2025, this field-led approach stayed central because buying decisions depend on clinician trust and procedure adoption, not broad consumer demand.
Service
In FY2025, AngioDynamics used service to support a business with about $304 million in net sales, making post-sale help more than a back-office task. Product training and clinical education help physicians use devices correctly, which matters in procedure-based markets where outcomes shape repeat use. Fast troubleshooting also cuts friction after purchase and helps protect adoption when hospitals compare support, not just device specs.
AngioDynamics' FY2025: $291M in Sales Fueled by Minimally Invasive Devices
AngioDynamics' primary activities in FY2025 centered on regulated device production, with about $291 million in net sales. Operations, outbound logistics, and field sales all depended on sterile handling, traceability, and clinician education to keep procedure-driven demand moving. Service stayed important too, because training and troubleshooting help protect adoption in hospitals and outpatient centers.
| Primary activity | FY2025 data |
|---|---|
| Net sales | $291M |
| Business focus | Minimally invasive devices |
Full Version Awaits
AngioDynamics Reference Sources
This preview shows the actual AngioDynamics Value Chain Analysis document you'll receive after purchase. There are no substitutions or sample-only sections – what you see is what you get. Once unlocked, the full report is available in the same professional format and detail.
Frequently Asked Questions
It emphasizes clinical innovation and regulated execution. AngioDynamics works across 2 reportable segments and 3 core disease areas, so R&D, quality, and commercial support have to stay tightly aligned. That matters most in minimally invasive procedures such as angioplasty, thrombolysis, and embolization, where physician confidence and device reliability drive use.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.